Compugen Announces In-Vivo Results for Two Novel Peptide Agonists of MAS GPCR
News Feb 13, 2008
Compugen Ltd. has announced the positive in-vivo results for two novel peptide agonists of the MAS G-protein coupled receptor (GPCR), indicating cardio-protective effects and therapeutic potential for the treatment of various cardiovascular and other pathologies.
The two peptides – CGEN-856 and CGEN-857 – were identified using the Company’s previously announced GPCR ligand discovery platform. The in-vivo results will be presented at the VII International Symposium on Vasoactive Peptides to be held February 14-16, 2008 in Brazil.
In an in-vivo model of cardiac remodeling, CGEN-856 and CGEN-857 were shown to afford significant cardio protection, as manifested by reduction of both fibrosis and hypertrophy of cardiomyocytes. Moreover, picomolar concentrations of the peptides had an anti-arrhythmogenic effect in isolated rat hearts following ischemia-reperfusion, as demonstrated by a reduction in the incidence and duration of reperfusion arrhythmias.
In addition, sub-nanomolar concentrations of these peptides demonstrated significant dose-dependant relaxation of rat aorta. Through the reduction of cardiac remodeling and a unique vasodilatatory effect, these peptides could offer a novel approach to heart failure and other cardiovascular conditions. Heart failure is a major cause of morbidity and mortality worldwide. It affects millions of people in the US and, despite continued efforts, mortality remains very high.
Molecular biologists long thought that domains in the genome’s 3D organization control how genes are expressed. After studying highly rearranged chromosomes in fruit flies, researchers now reveal that while this is the case for some genes, their results challenge the generality of this for many others.READ MORE